Risk-treatment mismatch in heart failure

摘要

Patients with heart failure at high risk of death are least likely to receive treatment with angiotensin-converting enzymes,angiotensin II receptor blockers and beta-blockers,say Canadian researchers.They analysed data from 1,418 hospital patients in Ontario,Canada,aged 79 years or younger,with a left ventricular ejection fraction of 40 per cent or less.They found that as predicted risk of death increased,discharge prescriptions for these drugs decreased.This pattern was maintained for up to one year after discharge.